ASX:EPI

3 stories mentioning ASX:EPIUpdated 1h ago

Every FINWIRES story that references ASX:EPI, newest first.

What's the latest news on ASX:EPI?

Epiminder Says US Clinical Study Evaluating Epilepsy Monitoring Platform Enrolls 75th Patient

Epiminder (ASX:EPI) said its Detect US clinical study enrolled its 75th patient, according to a Thursday Australian bourse filing.The recruitment is in line with expectations and the firm remains on track to enroll 210 patients by end of the first half of 2027, the firm's Chief Executive Rohan Hoare said.The study is evaluating the Minder system as a tool to improve clinical decision-making for patients with epilepsy following an inconclusive prolonged electroencephalographic monitoring assessment.The medical device company's shares rose nearly 2% in recent trading on Thursday.

ASX:EPI

Asia63d ago

Epiminder Reaches 50-Patient Enrollment Milestone in Epilepsy Study Ahead of Target

Epiminder (ASX:EPI) said it has now enrolled 50 patients in a US clinical study evaluating the Minder system as a tool to improve clinical decision-making for patients with epilepsy, according to a Thursday filing with the Australian bourse.The company hit the enrollment milestone in the Detect study ahead of its mid-third quarter target, and remains on track to enroll 210 patients by the end of the first half of 2027, per the filing.The Minder system is an implant placed under the scalp to continuously monitor brain waves."With 20 leading epilepsy centers now actively enrolling, we are seeing genuine, demonstrated adoption of the Minder System in a clinical setting," said Epiminder CEO Rohan Hoare.The company's shares gained over 1% in recent Thursday trade.

ASX:EPI

Asia108d ago

Epiminder Reaches 25 Enrolled Patients in Epilepsy Study

Epiminder (ASX:EPI) reached 25 enrolled patients in its DETECT (Diagnosing Epilepsy To EffeCT change) clinical study in the US, according to a Monday filing with the Australian bourse.The study is evaluating the Minder system, an implantable device for continuous monitoring of brain activity, as a tool to improve clinical decision-making for patients with epilepsy after an inconclusive prolonged electroencephalographic monitoring assessment, the filing said.The company is progressing toward its next enrolment target of 50 patients, expected in the third quarter of the year, and is on track to meet its stated target of 210 patients by the end of the first half of 2027, per the filing.

ASX:EPI

Track with the FINWIRES app suite

FolioX

Track ASX:EPI in your portfolio

WheelAI

Analyze ASX:EPI options with the wheel strategy

StockInsider

See market sentiment on ASX:EPI